BioCentury
ARTICLE | Emerging Company Profile

Metabolic contrarian

Why Antag thinks blocking GIP is better than agonizing it in metabolic disease

October 6, 2017 10:58 PM UTC

Antag Therapeutics ApS is going against the grain, blocking rather than boosting the effects of glucose-dependent insulinotropic polypeptide to treat obesity and diabetes.

While several other companies are developing agonists to enhance the peptide’s glucose-regulating activity, Antag believes the hormone loses its normal activity and becomes pathogenic during metabolic diseases. ...